Publications

Selected Peer-reviewed Publications (Selected from 108 peer-reviewed publications)
* Corresponding author

  1. Chong H, Qiu Z, Su Y, Yang L, He Y*. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket. AIDS  Oct 14 2014 [Epub of ahead]
  2. Chong H, Qiu Z, Sun J, Qiao Y, Li X, He Y*. (2014) Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK. Retrovirology. 11(1):40
  3. Chong H, Yao X, Qiu Z, Sun J, Qiao Y, Zhang M, Wang M, Cui S, He Y*. (2014) The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance. J Antimicrob Chemother. 69(10):2759-69.
  4. Wu R, Li X, Leung HC, Cao Z, Qiu Z, Zhou Y, Zheng BJ, He Y*.  (2014) A novel neutralizing antibody against diverse clades of H5N1 influenza virus and its mutants capable of airborne transmission.Antiviral Res. 106:13-23
  5. Chen W, Feng Y, Prabakaran P, Ying T, Wang Y, Sun J, Macedo CD, Zhu Z, He Y, Polonis VR, Dimitrov DS (2014) Exceptionally potent and broad bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol. 88(2):1125-39
  6. Xu L, Cai L, Chen X, Jiang X, Chong H, Zheng B, Wang K, He J, Chen W, Zhang T, Cheng M, He Y, Liu K. (2013) DNA Duplexes with Hydrophobic Modifications Inhibit HIV-1-cell Membrane Fusion. Antimicrob Agents Chemother. 57(10):4963-70
  7. Wan C, Sun J, Chen W, Yuan X, Chong H, Prabakaran P, Dimitrov D, He Y*. (2013) Epitope Mapping of M36, a Human Antibody Domain with Potent and Broad HIV-1 Inhibitory Activity.  PLoS One. 8(6) e66638
  8. Hofmann H, Li X, Zhang X, Liu W, Kühl A, Kaup F, Soldan SS, González-Scarano F, Weber F, He Y, Pöhlmann S. (2013) The severe fever with thrombocytopenia virus glycoproteins are targeted by neutralizing antibodies and can use DC-SIGN as receptor for pH-dependent entry into human and animal cell lines. J Virol. 87(8):4384-94
  9. Li K, Markosyan R, Zheng Y, Golfetto O, Bungart B, Li M, He Y, Liang C, Lee J, Gratton E, Cohen F, Liu S*. 2013. IFITM Proteins Restrict Viral Membrane Fusion by Blocking the Creation of Hemifusion. PLoS Pathog, 9(1): e1003124
  10. Chong H,Yao X,Qiu Z,Sun J,Zhang M,Walterspereger S,Wang M,Liu S,Cui S*, He Y*. (2013) Short peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1. FASEB J,27(3):1203-1213.
  11. He Y*. (2013) Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion (Invited review). Curr Pharm Des. 19(10):1800-1809
  12. Chong H, Yao X, Sun J, Qiu Z, Zhang M, Waltersperger S, Wang M, Cui S*, He Y*. (2012) The M-T hook structure is critical for design of HIV-1 fusion inhibitors. J Biol Chem, 287(41):34558-34568.
  13. Yao X, Chong H, Zhang C, Qiu Z, Qin B, Han R, Waltersperger S, Wang M, He Y*, Cui S*. (2012) Structural Basis of Potent and Broad HIV-1 Fusion Inhibitor CP32M. J Biol Chem  287(32):26618-26629.
  14. Chong H, Yao X, Qiu Z, Qin B, Han R, Waltersperger S, Wang M, Cui S*, He Y*. (2012) Discovery of Critical Residues for Viral Entry and Inhibition through Structural Insight of HIV-1 Fusion Inhibitor CP621-652. J Biol Chem. 287(24): 20281-20289.
  15. Cao Z, Meng J, Li X, Wu R, Huang Y, He Y*. (2012) The epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus. PLoS One. 7(5): e38126.
  16. Chong H, Yao X, Zhang C, Cai L, Cui S, Wang Y, He Y*. (2012) Biophysical property and broad anti-HIV activity of Albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.  PLoS One. 7(3): e32599.
  17. Yao X, Chong H, Zhang C, Waltersperger S, Wang M, Cui S*, He Y*. (2012) Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor Sifuvirtide. J Biol Chem. 287(9): 6788-6796.
  18. Bertram S, Glowacka I, Müller MA, Lavender H, Gnirss K, Nehlmeier I, Niemeyer D, He Y, Simmons G, Drosten C, Soilleux EJ, Jahn O, Steffen I, Pöhlmann S. (2011) Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol. 85(24):13363-72.
  19. Zhang C, Yang Y, Zhou X, Yang Z, Liu X, Cao Z, Song H, He Y*, Huang P* .(2011) The NS1 Protein of Influenza A Virus Interacts with Heat Shock Protein Hsp90 in Human Alveolar Basal Epithelial Cells: Implication for Virus-induced Apoptosis. Virol J. 8: 181.
  20. Liu L, Xie J, Sun J, Yang H, Zhang C, Fan H, Liu Z, Qiu Z, He Y*, Li T*. (2011) Longitudinal profiles of immunoglobulin G antibodies against SARS coronavirus components and neutralizing activities in recovered patients. Scand J Infect Dis. 43(6-7): 515-521
  21. Glowacka I, Bertram S, Allen P, Soileux E, Pfeferle S, Steffen I, Tsegaye T, He Y, Gnirss K, Niemeyer D, Muller M, Schneider H, Drosten C, Pohlmann S. (2011) Evidence that TRPRSS2 activates the SARS-cornavirus spike protein for membrane fusion and reduces viral control by the humoral immune responses. J Virol, ;85(9):4122-34.
  22. Liu Z, Shan M, Li L, Lu L, Meng S, Cheng C, He Y, Jiang S*, Zhang L*. (2011) In Vitro selection and characterization of HIV-1 variants with increased resistance to Sifuvirtide, a novel HIV-1 fusion inhibitor.  J Biol Chem, 286(5):3277-87
  23. Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T*, He Y*. (2010) Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Viral J, 7: 299
  24. Zhao G, Du L, Xiao W, Sun S, Lin Y, Chen M, Kou Z, He Y, Lustigman S, Jiang S, Zheng B*, Zhou Y*. (2010) Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation-associated protein-1 (ASP-1) adjuvant. Vaccine, 28(44): 7233-40
  25. Jia L, Xu Y, Zhang C, Wang Y, Chong H, Qiu S, Wang L, Zhong Y, Liu W, Sun Y, Qiao F, Tomlin S, Song H*, Zhou Y*, He Y*. (2010)A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement. Viral J, 7:142
  26. Du L, Zhao G, Chan C, He Y, Zhou Y, Zheng B, Jiang S*. (2010) A 219-mer CHO-expressing receptor-binding domain of SARS-CoV protein induces potent immune responses and protective immunity. Viral Immunol, 23(2): 211-9
  27. Zhang C, Yang Y, Zhou X, Song H, He Y*, Huang P*. (2010) Highly pathogenic avian influenza A virus H5N1 NS1 protein induces caspase-dependent apoptosis in human alveolar basal epithelial cells. Viral J, 7:51
  28. Du L, Zhao G, Chan C, Sun S, Chen M, Liu Z, Guo H, He Y, Zhou Y, Zheng B, Jiang S*. (2009) Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology  393:144-150.
  29. He Y*, Barker S, MacDonald A, Yu Y, Cao L, Li J, Parhar R, Heck S, Hartmann S, Golenbock D, Jiang S, Libri N, Semper A, Rosenberg W, Lustigman S. (2009) Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth onchocerca volvulus, can directly bind and activate antigen-presenting cells.  J Immunol; 182(7): 4098-4105
  30. Du L, Zhao G, Li L, He Y, Zhou Y, Zheng B, Jiang S*. (2009) Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun 384(4): 486-90
  31. Ji H*, Song W, Gao Z, Su X, Nie H, Jiang Y, Peng J, He Y, Liao Y, Zhou Y, Tousson A, Matalon S. SARS-CoV proteins decrease levels and activity of human ENaC via activation of distinct PKC isoforms. Am J Physiol Lung Cell Mol Physiol, 2009; 296(3): L372-83
  32. Du L, He Y, Zhou Y, Liu S, Zheng B, Jiang S*. (2009) The spike protein of SARS-CoV: a target for vaccine and therapeutic development. Nat Rev Microbiol. 7(3):226-236
  33. He Y*, Cheng J, Lu H, Li J, Hu J, Qi Z, Liu Z, Jiang S, Dai Q*. (2008) Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.  Proc Natl Acad Sci U S A.  105(42):16332-7.
  34. He Y*, Liu S, Li J, Lu H, Qi Z, Liu Z, Debnath AK, Jiang S.(2008)Conserved Salt-bridge between the N- and C-Terminal Heptad Repeat Regions of HIV-1 gp41 Core Structure Is Critical for Virus Entry and Inhibition. J  Virol; 82(22): 11129-11139
  35. He Y*, Chen J, Li J, Qi Z, Lu L, Dong M, Jiang S, Dai Q*. (2008) Identification of a critical motif for the HIV-1 gp41 core structure: Implication for designing novel anti-HIV fusion inhibitors.  J  Viol.  82(13): 6349-6358
  36. He Y, Xiao Y, Song H, Liang Q, Ju D, Chen X, Lu H, Jing W, Jiang S*, Zhang L*. (2008) Design and evaluation of Sifuvirtide: a novel HIV-1 fusion inhibitor.  J Biol Chem. 283(17): 11126-11134
  37. Xiao W, Du L, Liang C, Guan J, Jiang S, Lustigman S, He Y*, Zhou Y*. (2008)Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines. Vaccine 26(39):5022-9
  38. He Y*, Liu S, Jing W, Debnath A, Jiang S*  (2007).  Conserved residue Lys574 in the cavity of HIV-1 gp41 is critical for six-helix bundle formation and virus entry.  J Biol Chem. 282(35): 25631-9
  39. Zhu Z, Chakraborti S #, He Y #, Roberts A, Xiao X, Hensley L, Prabakaran P, Sidorov I, Vogel L, Feng Y, Kim J, Wang L, Baric R, Lanzavecchia A, Curtis K, Nabel G, Subbarao K, Jiang S, Dimitrov D*. (2007) Potent Cross-Reactive Neutralization of SARS Coronavirus Isolates by Human Monoclonal Antibodies. Proc Natl Acad Sci USA 104(29):12123-8. (# equal contribution)
  40. Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S, He Y, Jiang S, Wu C, Yuen KY, Jin DY, Zhou Y, Zheng B*. (2008) Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.  J Immunol. 180(2):948-56.
  41. Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, Zheng B*. (2008) Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 26(13):1644-51.
  42. Du L, He Y, Jiang S, Zheng B*. (2008) Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today (Barc). 44(1):63-73.
  43. Du L, Kao R, Zhou Y, He Y, Zhao G, Wong C, Jiang S, Yuen K, Jin D, Zheng B*. (2007) Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity.  Biochem Biophys Res Commun. 359(1):174-9.
  44. Du L, Zhao G, He Y*, Guo Y, Zheng B, Jiang S, Zhou Y*. (2007) The receptor-binding domain of SARS coronavirus spike protein elicits long-term protective immunity in an animal model.  Vaccine 25(15):2832-8
  45. Li T*, Xie J, He Y, Fan H, Baril L, Qiu Z, Han Y, Xu W, Zhang W, You H, Zou Y, Fang Q, Chen Z, Zhang L* (2006). Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus.  PLoS ONE.  1:e24.
  46. Du L, Wang Y, Shen C, He Y, Zheng B, Zhou Y*. (2006). Strong antigenicity and neutralizing antibody induced by recombinant proteins targeting the S1 region of SARS coronavirus imply for serodiagnosis and vaccine development.  J Lab Tech. 1(1):7-12
  47. He Y*. (2006). Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies. Adv Exp Med Biol. 581:539-42
  48. He L, Ding Y, Zhang Q, Che X, He Y, Shen H, Wang H, Geng J, Deng Y, Yang L, Li J, Cai J, Qiu L, Wen K, Xu X, Jiang S*. (2006). Over-expression of proinflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injure and pathogenesis of SARS.  J  Pathol.  210: 288-297
  49. 41.  Du L, He Y, Wang J, Ma S, Wong C, Wu S, Yuen K, Jiang. S, Zhou Y., Zheng B*. (2006) Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: implication for developing SARS vaccines.  Virology   353: 6-16
  50. He Y*, Li J, Du L, Yan X, Hu G, Zhou Y, Jiang S*. (2006). Identification and Characterization of novel neutralizing epitopes of the severe acute respiratory syndrome coronavirus: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.  Vaccine 24: 5498-508
  51. He Y*, Li J, Heck S, Lustigman S, Jiang S. (2006). Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.  J  Virol.  80: 5757-5767
  52. Lu H, Zhao Q, Wallace G, Liu S, He Y, Shattock R, Neurath A, Jiang S*. (2006) Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates. AIDS Res Hum Retroviruses 22:411-418
  53. He Y*, Li J, Li W, Lustigman S, Farrzan M., Jiang S. (2006) Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.  J.  Immunol.  176: 6085-6092
  54. He Y*, Li J, Heck S, Jiang S. (2006) A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. Biochem. Biophys. Res. Commun. 344: 106-113
  55. Tuen M, Visciano M, Chien P, Cohen S, Chen P, Robinson J, He Y, Pinter A, Gorny M, Hioe C*. (2005). Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation.  Eur J Immunol.  35: 2541-2551
  56. Zhao Q, Ma L, Jiang S, Lu H, Liu S, He Y, Strick N, Neamati Debnath A. (2005) Identification of N-Phenyl-N’-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.  Virology  339: 213-225
  57. Jiang S, He Y, Liu S. (2005). SARS vaccine development.  Emerg.  Infect. Dis.  11:1016-1020
  58. He Y, Jiang S. (2005). Vaccine design for severe acute respiratory syndrome coronavirus. Viral Immunl. 18: 327-332
  59. Liu S, Lu H, Zhao Q, He Y, Debnath A, Wu S, Jiang S. (2005). Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta 1723:270-281
  60. He Y, Jiang S. (2005). Antigenicity and immunogenicity of SARS-CoV.  eJBio. 1:21-26
  61. He Y, Zhou Y, Siddiqui P, Jiang S. (2005). Identification of immunodominant epitopes on the membrane protein of severe acute respiratory syndrome coronavirus.  J.  Clin.  Microbiol.  43:3718-3725
  62. MacDonald A, Cao L, He Y, Zhao Q, Jiang S, and Lustigman S. (2005). rOv-ASP-1, a recombinant secreted protein of the helminth, Onchocerca volvulus is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens. Vaccine 23:3446-3452
  63. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S. (2005). Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependant epitopes that induce highly potent neutralizing antibodies.  J. Immunol.  174: 4908-4915
  64. He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, Jiang S. (2005). Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.  Virology 334: 74-8
  65. He Y, Zhou Y, Siddiqui P, Jiang S. (2004). Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem. Biophys. Res. Commun. 325: 445-452
  66. He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, Jiang S. (2004). Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibody responses: implication for developing subunit SARS vaccine. Biochem. Biophys. Res. Commun. 324: 773-781
  67. He Y, Zhou Y, Wu H, Kou Z, Liu S, Jiang S. (2004). Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus.  J. Clin. Microbiol.  42: 5309-5314
  68. He Y, Zhou Y, Wu H, Luo B, Chen J, Li W, Jiang S. (2004). Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J. Immunol. 173:4050-4057
  69. Liu S, Xiao G,  Chen Y, He Y, Nui J, Escalante C,  Farmer J, Debnath A, Tian  P, Jiang S. (2004). Interaction between the heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus (SARS-CoV): implication for virus fusogenic mechanism and identification of fusion inhibitors.  Lancet 363: 938-47
  70. Jiang S, Lu H, Liu S, Zhao Q, He Y, Debnath A. (2004). Identification of N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.  Antimicrob Agents Chemother  48: 4249-4359
  71. Zhao Q, He Y, Alespeiti G, Debnath A.(2004). A novel assay to identify entry inhibitors that block binding of HIV gp120 to CCR5.  Virology  326: 299-309
  72. Pinter A, Honnen W, He Y, Gorny M,  Zolla-Pazner S,  Kayman SC  (2004). The V1/V2 domain of gp120 is a global regulator of sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection.        J.  Virol.  78:5205-5215
  73. He Y, D'Agostino P, Pinter A. (2003). Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins.  Vaccine    21: 4421-9
  74. Burkhart M, Kayman S, He Y, Pinter A. (2003). Distinct mechanism of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domains of murine leukemia virus SU.  J.  Virol.  77:3993-4003
  75. He Y, Honnen W, Krachmarov C, Kayman S, Corvalon J, Pinter A. (2002). Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci.  J.  Immunol.   169:595-605
  76. Zhang L, Lewin S, Markowitz M, Lin H, Skulsky E, Karanicolas R, He Y, Jin X., Tuttleton S, Vesanen M, Spiegel H, Kost R, Lunzen J, Stellbrink H, Wolinsky S, Borkowsky W, Palumbo P, Kostrikis L, Ho D. (1999). Measuring recent thymic emigrants in blood of normal and HIV-1 infected individuals before and after effective therapy.  J. Exp. Med. 190:725-32
  77. Zhang L, Ramratnam B, TennerRacz K, He Y, Vesanen M,  Lewin S, Talal A, Racz P, Perelson A, Korber B, Markowitz M, Ho D.(1999). Quantifying residual HIV-1 replication in patients receiving combination antiretrovial therapy.  N. Eng. J. Med.   340:1605-13
  78. Wang X, He Y, Zhou Y, Liu S, Tian P. (1999). Construction of human combinatorial antibody library and screening of monoclonal antibody Fabs to HIV-1. Chin. Sci. Bull.  44:352
  79. Xu D, He Y, Zheng L. (1997). Retreatment of chronic HCV infection with interferon alpha and thymosin alpha-1.   Hepatol.   26(suppl): 2007
  80. Liu B, He Y, Miao Q, Wang H. (1994).The effects of tetrandring (TT) and polyvinylpyridine-N-oxide (PVNO) on gene expression of type I and III collagens during experimental silicosis.  Biomed Env Sci   7:199-204

 

 

 

Yuxian He

Professor

 


  • DEPARTMENTChinese Academy of Medical Sciences & Peking Union Medical College

  • COUNTRY BEIJING